[Federal Register Volume 73, Number 202 (Friday, October 17, 2008)]
[Notices]
[Page 61909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-24767]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 5, 2008, Noramco Inc., 
Division of Ortho McNeil, Inc., 500 Swedes Landing Road, Wilmington, 
Delaware 19801-4417, made application by renewal to the Drug 
Enforcement Administration (DEA) as a bulk manufacturer of the basic 
classes of controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053).....................  I
Dihydromorphine (9145).....................  I
Morphine-N-oxide (9307)....................  I
Methylphenidate (1724).....................  II
Methylphenidate HCL (1726).................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Opium extracts (9610)......................  II
Opium fluid extract (9620).................  II
Opium tincture (9630)......................  II
Opium, powdered (9639).....................  II
Opium, granulated (9640)...................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the above listed controlled 
substances for sale and distribution to manufacturers for product 
development and formulation.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than December 16, 2008.

    Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-24767 Filed 10-16-08; 8:45 am]
BILLING CODE 4410-09-P